# US 2016/0355808 A1 · OLIGONUCLEOTIDE COMPOUNDS FOR TARGETING HUNTINGTIN mRNA

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355808 A1
- Document ID: US20160355808A1
- Status: Published application
- Kind: A1
- Application number: 15/089,319
- Filed: 2016-04-01
- Published: 2016-12-08
- Earliest claimed: 2015-04-03
- Assignees: University of Massachusetts
- Applicants: University of Massachusetts
- Inventors: Anastasia Khvorova; Neil Aronin; Julia Alterman
- Web page: https://patentgrep.com/patent/US20160355808A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 9/0085: {Brain, e.g. brain implants; Spinal cord}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/343: having patterns, e.g. ==--==--==--
- C12N 2310/344: Position-specific modifications, e.g. on every purine, at the 3'-end
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- C12N 2310/3517: Marker; Tag
- C12N 2310/3519: Fusion with another nucleic acid
- C12N 2310/52: branched
- C12N 2320/11: for the determination of target sites, i.e. of active nucleic acids
- C12N 2320/30: Special therapeutic applications
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2320/51: modulating the chemical stability, e.g. nuclease-resistance
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure relates to novel huntingtin targets. Novel oligonucleotides for the treatment of Huntington's disease are also provided.

## Claims

### Claim 1

An RNA molecule that is between 15 and 35 bases in length, comprising a region of complementarity which is substantially complementary to 5′ CAGUAAAGAGAUUAA 3′ (SEQ ID NO:1), 5′ AUAUCAGUAAAGAGA 3′ (SEQ ID NO:2) or 5′ CUCAGGAUUUAAAAU 3′ (SEQ ID NO:3).

### Claim 2 (depends on 1)

The RNA molecule of claim 1, wherein said RNA molecule is single stranded (ss) RNA or double stranded (ds) RNA,
wherein the dsRNA optionally comprises one or more of the following:
a sense strand and an antisense strand, wherein the antisense strand comprises the region of complementarity which is optionally: substantially complementary to 5′ CAGUAAAGAGAUUAA 3′ (SEQ ID NO:1), 5′ AUAUCAGUAAAGAGA 3′ (SEQ ID NO:2) or 5′ CUCAGGAUUUAAAAU 3′ (SEQ ID NO:3); is complementary to at least 10, 11, 12 or 13 contiguous nucleotides of SEQ ID NO:1, 2 or 3; contains no more than 3 mismatches with SEQ ID NO:1, 2 or 3; or is fully complementary to SEQ ID NO:1, 2 or 3;
is between 30 and 35 base pairs in length;
is blunt-ended;
comprises at least one single stranded nucleotide overhang;
comprises naturally occurring nucleotides;
comprises at least one modified nucleotide optionally chosen from the group consisting of a 2′-O-methyl modified nucleotide, a nucleotide comprising a 5′phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group; said modified nucleotide is chosen from the group consisting of a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, at least one 2′-O-methyl modified nucleotide and at least one nucleotide comprising a 5′phosphorothioate group; and
comprises a cholesterol moiety.

### Claim at position 3

3-14. (canceled)

### Claim 15 (depends on 2)

A pharmaceutical composition for inhibiting the expression of Huntingtin (HTT) gene in an organism, comprising the dsRNA of claim 2 and a pharmaceutically acceptable carrier.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The RNA molecule of claim 1, wherein the RNA molecule comprises a 5′ end, a 3′ end and has complementarity to a target, wherein:
(1) the RNA molecule comprises alternating 2′-methoxy-ribonucleotides and 2′-fluoro-ribonucleotides;
(2) the nucleotides at positions 2 and 14 from the 5′ end are not 2′-methoxy-ribonucleotides;
(3) the nucleotides are connected via phosphodiester or phosphorothioate linkages; and
(4) the nucleotides at positions 1-6 from the 3′ end, or positions 1-7 from the 3′ end, are connected to adjacent nucleotides via phosphorothioate linkages.

### Claim 18 (depends on 2)

The dsRNA of claim 2, said dsRNA having a 5′ end, a 3′ end and complementarity to a target, and comprising a first oligonucleotide and a second oligonucleotide, wherein:
(1) the first oligonucleotide comprises a sequence set forth as SEQ ID NO:1;
(2) a portion of the first oligonucleotide is complementary to a portion of the second oligonucleotide;
(3) the second oligonucleotide comprises alternating 2′-methoxy-ribonucleotides and 2′-fluoro-ribonucleotides;
(4) the nucleotides at positions 2 and 14 from the 3′ end of the second oligonucleotide are 2′-methoxy-ribonucleotides; and
(5) the nucleotides of the second oligonucleotide are connected via phosphodiester or phosphorothioate linkages.

### Claim 19 (depends on 18)

The nucleic acid of claim 18 comprising one or more of the following:
the second oligonucleotide is linked to a hydrophobic molecule at the 3′ end of the second oligonucleotide;
the linkage between the second oligonucleotide and the hydrophobic molecule comprises polyethylene glycol or triethylene glycol;
the nucleotides at positions 1 and 2 from the 3′ end of second oligonucleotide are connected to adjacent nucleotides via phosphorothioate linkages; and
the nucleotides at positions 1 and 2 from the 3′ end of second oligonucleotide, and the nucleotides at positions 1 and 2 from the 5′ end of second oligonucleotide, are connected to adjacent ribonucleotides via phosphorothioate linkages.

### Claim at position 9

20-22. (canceled)

### Claim 23 (depends on 2)

A method for inhibiting expression of HTT gene in a cell, the method comprising:
(a) introducing into the cell a double-stranded ribonucleic acid (dsRNA) of claim 2; and
(b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of the HTT gene, thereby inhibiting expression of the HTT gene in the cell.

### Claim 24 (depends on 2)

A method of treating or managing Huntington's disease comprising administering to a patient in need of such treatment or management a therapeutically effective amount of said dsRNA of claim 2.

### Claim 25 (depends on 2, 24)

The method of claim 24 comprising one or more of the following:
said dsRNA is administered to the brain of the patient;
said dsRNA is administered by intrastriatal infusion;
administering the dsRNA of claim 2 to the brain causes a decrease in HTT gene mRNA in the striatum; and
administering the dsRNA of claim 2 to the brain causes a decrease in HTT gene mRNA in the cortex.

### Claim at position 13

26-28. (canceled)

### Claim 29

A vector for inhibiting the expression of HTT gene in a cell, said vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes an RNA molecule substantially complementary to 5′ CAGUAAAGAGAUUAA 3′ (SEQ ID NO:1), 5′ AUAUCAGUAAAGAGA 3′ (SEQ ID NO:2) or 5′ CUCAGGAUUUAAAAU 3′ (SEQ ID NO:3), wherein said RNA molecule is between 10 and 35 bases in length, and wherein said RNA molecule, upon contact with a cell expressing said HTT gene, inhibits the expression of said HTT gene by at least 20%.

### Claim 30 (depends on 29)

The vector of claim 29, wherein: said RNA molecule is a ssRNA or dsRNA, wherein the dsRNA optionally:
comprises a sense strand and an antisense strand, wherein the antisense strand comprises the region of complementarity which is substantially complementary to 5′ CAGUAAAGAGAUUAA 3′ (SEQ ID NO:1); or
is between 30 and 35 base pairs in length.

### Claim 31

(canceled)

### Claim 32 (depends on 30)

A cell comprising the vector of claim 30.

### Claim at position 18

33-46. (canceled)

### Claim 47 (depends on 34)

A pharmaceutical composition for inhibiting the expression of the HTT gene in an organism, comprising the dsRNA of claim 34 and a pharmaceutically acceptable carrier.

### Claim at position 20

48-68. (canceled)

### Claim 69

A dsRNA molecule that is between 15 and 35 bases in length, comprising a region of complementarity which is substantially complementary to 5′ CAGUAAAGAGAUUAA 3′ (SEQ ID NO:1), 5′ AUAUCAGUAAAGAGA 3′ (SEQ ID NO:2) or 5′ CUCAGGAUUUAAAAU 3′ (SEQ ID NO:3), wherein the RNA molecule targets an HTT mRNA and comprises at least one modified nucleotide.

### Claim 70 (depends on 69)

The dsRNA of claim 69, wherein said modified nucleotide is a terminal nucleotide linked to a phosphatidylcholine derivative.

### Claim 71

A di-branched RNA compound comprising two RNA molecules that are between 15 and 35 bases in length, comprising a region of complementarity which is substantially complementary to 5′ CAGUAAAGAGAUUAA 3′ (SEQ ID NO:1), 5′ AUAUCAGUAAAGAGA 3′ (SEQ ID NO:2) or 5′ CUCAGGAUUUAAAAU 3′ (SEQ ID NO:3), wherein the two RNA molecules are connected to one another by one or more moieties independently selected from a linker, a spacer and a branching point.

### Claim 72 (depends on 1)

The RNA molecule of claim 1 optionally comprising one or more of the following:
said RNA molecule is an antisense molecule or a GAPMER molecule;
said antisense molecule is an antisense oligonucleotide;
said antisense molecule enhances degradation of the region of complementarity, wherein said degradation is optionally nuclease degradation; and
said nuclease degradation is mediated by RNase H.

### Claim at position 25

73-76. (canceled)
